DarioHealth (DarioHealth) Risk Assessment

View and export this data going back to 2013. Start your Free Trial

What is DarioHealth Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of DarioHealth is: High Risk: High uncertainty.

Competitive Comparison of DarioHealth's Risk Assessment

For the Health Information Services subindustry, DarioHealth's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DarioHealth's Risk Assessment Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, DarioHealth's Risk Assessment distribution charts can be found below:

* The bar in red indicates where DarioHealth's Risk Assessment falls into.

DarioHealth (NAS:DRIO) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

DarioHealth Risk Assessment Related Terms

Thank you for viewing the detailed overview of DarioHealth's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

DarioHealth (DarioHealth) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DarioHealth Corp (NAS:DRIO) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 W. 18th Street, New York, NY, USA, 10011

Website

https://www.mydario.com

DarioHealth Corp is a digital health company. It offers user-centric a multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. DarioHealth serves customers globally.

Executives

Jon H. Kaplan	director	1573 MALLORY LANE, SUITE 100, BRENTWOOD TN 37027
Erez Raphael	director, officer: Chief Executive Officer	9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Dennis M Mcgrath	director	C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Dror Bacher	officer: Chief Operating Officer	9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK L3 3088900
Oded Cohen	officer: GM MSK	8 HATOKHEN ST., CAESAREA INDUSTRIAL PARK L3 3088900
Adam K Stern	director	STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Dennis Matheis	director	8 HATOKHEN ST., CAESAREA L3 38900
Yoav Shaked	director	8 HATOKHEN ST., CAESAREA L3 3088900
Yadin Shemmer	director	8 HATOKHEN ST., CAESAREA L3 3088900
Richard Allan Anderson	officer: President, GM of North America	C/O DARIOHEALTH CORP., 18 W. 18TH ST, 5TH FLOOR, NEW YORK NY 10011
Yalon Farhi	director	C/O LABSTYLE INNOVATIONS CORP., 9 HALAMISH ST., CAESAREA INDUSTRIAL PARK, CAESAREA L3 3088900
Hila Karah	director	9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Zvi Ben-david	officer: Chief Financial Officer	9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Glen Moller	director	8 HATOKHEN ST., CAESAREA L3 3088900
Olivier Roger Jarry	officer: See Remarks	15 ROCKRIDGE RD, LARCHMONT NY 10538-3918